Zelboraf is an oral, small molecule kinase inhibitor indicated for the treatment of patients with BRAF V600 mutation-positive advanced or inoperable melanoma. It is designed to inhibit some mutated forms of BRAF, which cause abnormal signalling inside cancer cells leading to tumour growth.
Zelboraf is approved in the US, EU, Switzerland and many other countries across the world. Zelboraf was co-developed under a 2006 licence and collaboration agreement between Roche and Plexxikon, now a member of the Daiichi Sankyo Group.